Glyxambi (empagliflozin and linagliptin) Tablets 25 mg/5 mg 30 tablets Rx only NDC 0597-0164-30 Dist. by: Boehringer Ingelheim (BI) Pharmaceuticals, Inc. Ridgefield, CT 06877 USA
Published June 2, 2021 · Recall initiated: March 15, 2021
Summary
FDA records drug Class II recall D-0455-2021, published June 2, 2021 and initiated March 15, 2021. Recalling firm: Cardinal Health Inc.; Status: Terminated; Reported quantity: 592 bottles; Lot: 3513. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
What to do
Voluntary: Firm initiated · Letter
Get an email if GLYXAMBI has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- GLYXAMBI
- Manufacturer
- Cardinal Health Inc.
- Distributor
- FL, GA, SC
- Lot
- 3513
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAATROVENT HFA 17MCG 12.9GM; NDC/UPC 597008717; RX; INHALER MEDICAL INTERNAL - MAY OR MAY NOT BE AEROSOLJune 2, 2021
- FDASynjardy (empagliflozin and metformin hydrochloride) Tablets 12.5 mg/1000 mg 60 tablets Rx only NDCJune 2, 2021
- FDASpiriva HandiHaler (tiotropium bromide inhalation powder) For Oral Inhalation Only 18 mcg (as tiotropium) perJune 2, 2021
- FDAJentadueto XR (linagliptin and metformin hydrochloride extended-release) Tablets 5 mg/1000 mg 30 tablets RxJune 2, 2021
- FDACATAPRES-TTS-2 1X4; NDC/UPC 597003234; RX; ADHESIVE PATCHESJune 2, 2021
- FDASynjardy XR (empagliflozin and metformin hydrochloride extended-release) Tablets 25 mg/1000 mg 30 tablets RxJune 2, 2021
Questions about this recall
Was Glyxambi (empagliflozin and linagliptin) Tablets 25 mg/5 mg 30 tablets Rx only NDC 0597-0164-30 Dist. by: Boehringer Ingelheim (BI) Pharmaceuticals, Inc. Ridgefield, CT 06877 USA recalled?
Yes. FDA published recall D-0455-2021 on June 2, 2021. Reported hazard: CGMP Deviations: Intermittent exposure to temperature excursion during storage.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: GLYXAMBI.